Neurochem Gets Second FDA “Approvable” Letter For Kiacta
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA suggests that it may require an additional clinical efficacy trial with a p-value of 0.05 or less.
You may also be interested in...
Neurochem Will Resubmit Kiacta After Conducting New Phase III Study
Company pulls NDA for AA amyloidosis therapy, currently "approvable" at FDA, while it conducts a new trial.
Neurochem Will Resubmit Kiacta After Conducting New Phase III Study
Company pulls NDA for AA amyloidosis therapy, currently "approvable" at FDA, while it conducts a new trial.
Neurochem Drops Phase III Alzheimer’s Disease Candidate, Refocuses Pipeline
Firm will move a tramiprosate pro-drug into preclinical development and launch Alzhemed as a nutraceutical, in line with a new business model.